Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


24.07.2017

1 Am J Gastroenterol
1 Ann Intern Med
2 Dig Dis Sci
1 Eur J Gastroenterol Hepatol
1 Gastroenterology
1 Gut
4 Hepatology
2 J Clin Gastroenterol
1 J Interferon Cytokine Res
2 J Viral Hepat
1 J Virol
1 PLoS One
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Gastroenterol

  1. PELLICANO R
    Is Viral Hepatitis Decreasing in the United States?
    Am J Gastroenterol. 2017;112:1170.
    PubMed     Text format    


    Ann Intern Med

  2. SACKS HS
    Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response.
    Ann Intern Med. 2017;167:JC3.
    PubMed     Text format    


    Dig Dis Sci

  3. LIN XJ, Lao XM, Shi M, Li SP, et al
    Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment.
    Dig Dis Sci. 2016.
    PubMed     Text format     Abstract available

  4. PECTASIDES E, Miksad R, Pyatibrat S, Srivastava A, et al
    Spontaneous Regression of Hepatocellular Carcinoma with Multiple Lung Metastases: A Case Report and Review of the Literature.
    Dig Dis Sci. 2016.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  5. LIONCO LC, de Mattos AA, Horbe AF, Costabeber AM, et al
    Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil.
    Eur J Gastroenterol Hepatol. 2017;29:225-230.
    PubMed     Text format     Abstract available


    Gastroenterology

  6. YU MW, Lin CL, Liu CJ, Yang SH, et al
    Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-related Death in Men with Chronic Hepatitis B: A Large Cohort Study.
    Gastroenterology. 2017 Jul 12. pii: S0016-5085(17)35866.
    PubMed     Text format     Abstract available


    Gut

  7. JENDREK ST, Gotthardt D, Nitzsche T, Widmann L, et al
    Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Gut. 2016 Jul 12. pii: gutjnl-2016-311739. doi: 10.1136/gutjnl-2016-311739.
    PubMed     Text format     Abstract available


    Hepatology

  8. LOK AS, Chung RT, Vargas HE, Kim AY, et al
    Comments on Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Hepatology. 2017 Jul 16. doi: 10.1002/hep.29366.
    PubMed     Text format    

  9. PERSICO M, Aglitti A, Caruso R, De Renzo A, et al
    Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29364.
    PubMed     Text format     Abstract available

  10. KONERMAN MA, Thomson M, Gray K, Moore M, et al
    Impact of an Electronic Health Record Alert in Primary Care on Increasing Hepatitis C Screening and Curative Treatment for Baby Boomers.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29362.
    PubMed     Text format     Abstract available

  11. ROSEN HR, Ghany M, Chung R, Lok A, et al
    NAM 2017 Report: A National Plan To Eliminate Hepatitis B and C In the United States By 2030 And The AASLD's Response.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29361.
    PubMed     Text format    


    J Clin Gastroenterol

  12. WAN Z, Zhou A, Zhu H, Lin X, et al
    Maternal Hepatitis B Virus Infection and Pregnancy Outcomes: A Hospital-based Case-control Study in Wuhan, China.
    J Clin Gastroenterol. 2017 Jul 18. doi: 10.1097/MCG.0000000000000842.
    PubMed     Text format     Abstract available

  13. WONG VW, Hui AJ, Wong GL, Chan RS, et al
    Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients.
    J Clin Gastroenterol. 2017 Jul 18. doi: 10.1097/MCG.0000000000000852.
    PubMed     Text format     Abstract available


    J Interferon Cytokine Res

  14. BHUSHAN A, Ghosh S, Bhattacharjee S, Chinnaswamy S, et al
    Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-alpha-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection.
    J Interferon Cytokine Res. 2017 Jul 20. doi: 10.1089/jir.2017.0002.
    PubMed     Text format     Abstract available


    J Viral Hepat

  15. SOLOMON SS, Sulkowski MS, Amrose P, Srikrishnan AK, et al
    Directly Observed Therapy of Sofosbuvir/Ribavirin +/- Peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12761.
    PubMed     Text format     Abstract available

  16. JACKA B, Bray B, Applegate TL, Marshall BD, et al
    Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12758.
    PubMed     Text format     Abstract available


    J Virol

  17. SOORYANARAIN H, Rogers AJ, Cao D, Haac MER, et al
    ISG15 modulates type-I interferon signaling and antiviral response during hepatitis E virus replication.
    J Virol. 2017 Jul 19. pii: JVI.00621-17. doi: 10.1128/JVI.00621.
    PubMed     Text format     Abstract available


    PLoS One

  18. ANDRE-GARNIER E, Besse B, Rodallec A, Ribeyrol O, et al
    An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.
    PLoS One. 2017;12:e0179562.
    PubMed     Text format     Abstract available


    Virology

  19. MA J, Li T, Han X, Yuan H, et al
    Discovery and mechanism of action of Novel Baicalein modified derivatives as potent antihepatitis agent.
    Virology. 2017;507:199-205.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: